New Book Release: Patent Agent Examination

One of my close friend and indeed a dedicated and knowledgeable patent professional, Sheetal Chopra has recently wrote an interesting reference book on patents particularly for readers preparing and appearing for patent agent qualifying examination. This is a commendable effort by her to provide students as well as professionals who are aspiring to become patent agent with relevant study material useful for preparing and qualifying patent agent examination. Sheetal is a qualified organic chemist and registered patent agent with rich experience in handling complex patent issues while working with India’s largest global generic company Ranbaxy before joining FICCI. At FICCI, she has been very instrumental in raising industry’s concerns regarding intellectual property laws and policies, and also bridging much-needed gap between industry and policy-makers. Notably, she is been actively involved in conducting and promoting various IP awareness seminars and workshops across the country.

Her book surely will be of great resource for readers which not only explain the substantive and procedural patent laws in detail but also provide model answers to previous years’ question papers and useful tips on the viva voce. I am grateful to Sheetal for considering and giving me an opportunity to review her book before going into publication. And it is must recommended for those who are keen to understand Indian patent laws and looking to appear for patent agent qualifying examination. The book is published by LexisNexis the details of which can be found here.

US Patent Litigation Updates

Widely read biotech and pharma patent law blog, PatentDocs reported some of the latest patent infringement disputes involving Indian drug manufactures.

Oscient Pharmaceuticals Corp. et al. v. Lupin Ltd. et al

Oscient Pharmaceuticals Corporation, holder of the NDA license for anti-cholesterol drug Antara (generically Fenofibrate) jointly with Guardian II Acquisition Corporation and Ethypharm has filed a civil action for patent infringement against Pune-based Lupin Ltd. for infringement of Orange-Book listed US Patent No. 7,101,574 (“Pharmaceutical composition containing fenofibrate and the preparation method”). The ‘574 patent is issued to Ethypharm and exclusively licensed to Guardian II.

Wyeth v. Torrent Pharmaceuticals Ltd. et al

Ahmedabad-based Torrent Pharmaceuticals Ltd. is accused of patent infringement by Wyeth for infringement of Orange Book listed US Patent Nos. 6,274,171 (“Extended release formulation of venlafaxine hydrochloride”), 6,403,120 (“Extended release formulation of venlafaxine hydrochloride”), and 6,419,958 (“Extended release formulation of venlafaxine hydrochloride”) for anti-depressant drug Effexor XR (generically Venlafaxine extended release).

Dr. Reddy’s Laboratories Ltd. et al. v. Eli Lilly & Co

Dr. Reddy’s Laboratories Ltd. has filed a motion for declaratory judgment of non-infringment, invalidity, and unenforceability of US Patent Nos. 5,910,319 (“Fluoxetine enteric pellets and methods for their preparation and use”), 5,985,322 (“Method for the treatment of CNS disorders”), and RE39,030 (“Fluoxetine enteric pellets and methods for their preparation and use”) with respect to Dr. Reddy’s ANDA for generic Prozac Weekly (generically Fluoxetine delayed release pellets).

From the Desk of Patent Circle: Is Dasatinib Order Contravenes Bolar-Provision?

Continuing from our earlier post, we will now focus on another issue whether the Delhi HC Dasatinib order contravenes bolar-provision? However, before going further into details of this let us briefly discuss what is bolar-provision?

Bolar-provision, also referred as Regulatory-use exemption is a statutorily created exemption from the patent infringement under Sec. 107A (1) of the Patents Act, 1970 which states –

(a) any act of making, constructing, using, selling or importing a patented invention solely for uses reasonably related to the development and submission of information required under any law for the time being in force, in India, or in a country other than India, that regulates the manufacture, construction, use, sale or import of any product;

In simple words, the exclusive right conferred under Sec. 48 does not extend to prevent third party from any act specifically and reasonably necessary in the development and submission of information required under regulatory laws in India or any other country. The bolar-provision is of high importance to generic manufacturers to conduct certain trials on patented drug needed to generate data to demonstrate bioequivalence prior to the expiry of the patent. The purpose of bolar-provision is to ensure that the generic drugs are on the market immediately after the patent expiry – we again emphasize immediately after the patent expiry, not during the lifetime of the patent. In other words, the bolar-provision allows generic manufacturer to use and make patented drug for conducting necessary trials to generate data to demonstrate bioequivalence and to prove the drug is similar to the reference product (as needed by the Drug Regulatory agencies) without the consent of the patentee. However, exemption under Sec. 107A (1) does not extend to use of patented drug to obtain the license to manufacture and distribute the generic drug before the patent expiry.

We would like to add a word of caution that the bolar-provision exempts use of patented product (drug) to generate necessary regulatory data, not use of patented product to obtain license to manufacture and distribute the drug before the patent expiry and not even to induce willful patent infringement. Usually applicability of the bolar-provision comes in use just couple of years before the patent expiry not at least 10-12 years before the expiration.

Now coming back to our main issue – whether the Delhi HC Dasatinib order contravenes Bolar-provision? Considering (1) the scope of Sec. 107A (1) allows “the use” of patented product to generate bioequivalence data and (2) Hetero while seeking generic drug approval would have generated and submitted the same to the DCGI, it seems there is no contravention of “bolar-provision” by the Delhi HC Dasatinib order. In fact, if the DCGI gives Hetero the approval for marketing and Hetero possibly launches the drug before patent expiry then in such case none of Hetero’s action will be exempted under Sec. 107A (1) and will definitely lead to a case of blatant willful infringement. It is quite unfortunate that exemption under Sec. 107A (1) is distortedly portrayed as statutory go-ahead for willful infringement.

On the lighter note, if Hetero has already conducted bioequivalence studies without having a bona fide intention to launch the generic drug after the patent expiry then Hetero cannot seek immunity under Sec. 107A (1) and has already made a case of patent infringement, possibly willful …

From the Desk of Patent Circle: Delhi HC Dasatinib Order

A patent has no value if it cannot be monitored and enforced under the law and Indian patent is no exception to it. Though the Indian Patent Office (IPO) has started granting patents for drug compounds but industry runs serious concerns about their enforceability. Enforcement is not possible without proper and regulated monitoring which is already a major problem in fragmented Indian drug industry and the gravity of which can be gauged by the fact that about 20 percent drugs marketed in India are spurious drugs despite having both Central and State drug regulatory agencies. Both domestic and foreign companies are constantly struggling to tackle and raid counterfeit and spurious drugs in India. Even the government has shown serious concern over spurious drugs and has brought the Drugs and Cosmetic (Amendment) Bill, 2008 which is already been passed by both the Houses of Parliament and lately got approval of the President. However, the issue of spurious drug is not our main concern of discussion here it is just to give an idea about what extreme damage lack of proper monitoring policies can bring to Indian drug industry and consumer. Our focus of discussion is a recent order of the Delhi High Court (HC) restraining generic Dasatinib. Albeit we are bit late in reporting on this but still personally believe that the Delhi HC order got invariably distorted in the news media. So we thought running a post on the Delhi HC Dasatinib Order.

Dasatinib is an anti-cancer drug belonging to the class of tyrosine kinase inhibitors first approved in the United States on June 28, 2006 and marketed by Bristol-Myer Squibb (BMS) under the brand name Sprycel. BMS has a granted Indian patent (IN203937) for drug compound dasatinib conferring BMS the exclusive right under Sec. 48 of the Patents Act, 1970 to prevent third parties, who do not have his consent, from the act of making, using, offering for sale, selling or importing dasatinib in India. Regardless of patent protection, Hyderabad-based generic manufacturer Hetero Drugs submitted an application with the Drug Controller General of India (DCGI) for a grant of license to manufacture and distribute generic dasatinib tablets in India. Although BMS said to inform Hetero about the dasatinib patent but Hetero kept unanswered to BMS and continued to pursue its application before the DCGI. Clearly, the DCGI approval of license for generic dasatinib would have been a blatant violation of BMS right under Sec. 48 of the Patents Act, 1970. What is important to note that patent is a statutory right created by the legislature and it is duty of the executive (government) to enforce the right of the patentee. Also, it would be a complete mockery of jurisprudential aspect of ‘right’ if one government body (Indian Patent Office) confers BMS the exclusive right to prevent third parties from the act of making, using or selling dasatinib in India and the other government body (DCGI) dilutes, in fact, ignores the same right by issuing license to third party for making and selling dasatinib in India.

In law, there is a well-established legal maxim that says “ubi jus ibi remedium”: where there is a right, there is a remedy. Now in absence of any legal provision which would have prevented Hetero from pursuing application before the DCGI or would have authorized the DCGI to stop regulatory approval for generic version of patented drug, BMS had valid grounds and reason for approaching the judiciary for remedy against its right under Sec. 48 of the Patents Act, 1970. To make an appropriate case, BMS sought a legal recourse under Sec. 151 of the Code of Civil Procedure (CPC) from the Court to pass an ex parte ad interim order to restrain Hetero from manufacturing, selling, distributing, advertising, exporting or offering for sale generic dasatinib, and also an ex parte relief to restrain Hetero from pursuing their application before the DCGI. Sec. 151 of CPC triggers inherent powers of Court particularly in cases where there is no specific provision provided under the law. The Court is open to pass an appropriate consequential order under Sec. 151 of CPC as may as necessary for ends of justice.

After hearing BMS counsel and considering a prima facie case for grant of ex parte ad interim order, the Court restrained Hetero from manufacturing, selling, distributing, advertising, exporting or offering for sale generic Dasatinib. While referring BMS ex parte relief of restraining Hetero from pursuing their application before the DCGI, the Court added that it is expected that the DCGI while performing statutory functions will not allow any party to infringe any laws and if the drug for which approval has been sought by defendants (Hetero) is in breach of the patents of plaintiffs (BMS), the approval ought not to be granted to the defendants (Hetero). The Court further instructed BMS to make a representation to the DCGI within one week making out a case that Hetero generic drug for which approval has been sought being in breach of the patent granted to BMS.

Important to note that the learned Judge knowing that there is no legal provision to restrain the DCGI from approving the application for generic Dasatinib, has diligently and aptly used the word ‘ought’ while referring BMS ex parte relief of restraining Hetero from pursuing application before the DCGI. In fact, the Delhi HC order finds reasonable support in Sec. 2 of the Drugs & Cosmetic Act, 1940 (DCA) which states that the provisions under DCA shall be in addition to and not in derogation of any other law for the time being in force. Further it is important to note that this is just a temporary order which is passed to stop Hetero generic dasatinib during the pendency of the trial and also the order is restrictively limited to Hetero case. Till here, both the Delhi HC and BMS acted within the periphery of the law. The order nowhere creates any ‘patent-drug regulatory’ linkage or authorizes the DCGI to monitor drug patents and framing such an opinion at this moment when the Delhi HC has not even started hearing on the issue (just made a temporary order) and judgment still awaited is completely irrational. The issue is been unnecessarily sensationalized by the newspaper media, further creating more confusion and chaos among the domestic pharma companies and patent practitioners, however, the whole dasatinib episode has surely left us with few questions that now need utmost attention.

(1) Whether approval of generic version of a patented drug violates the exclusive right of the patentee under Sec. 48 of the Patents Act, 1970?

(2) Is there a need to formulate substantive and procedural laws under Drugs & Cosmetic Act, 1940 regarding approval of generic version of a patented drug?

(3) How enforcement of drug patents feasible in India?

(4) Is ‘patent-drug regulatory’ linkage a necessity?

(5) Importantly is India really serious about drug patents or possibly we are moving toward creating more chaos?

The Delhi HC order has surely opened a wide platform for policy discussions, particularly related to ‘patent-drug regulatory’ linkage and enforcement of patent right.

Indian Patent Examiners Inching at Par with Global Counterparts

Beginning 2009 I completed four years in patent practice after completing post-graduation specialization in patent laws from National Law University Jodhpur. It was an exciting journey so far, full of challenges, great learning and some personal achievements. I still clearly remember my first experience visiting Mumbai Patent Office, feeling both nervous and excited. Being a patent practitioner and knowing the gravity and depth of this complex profession I always had a great respect and regard for Patent Examiners. Believe me role of a Patent Examiner is no joke and require unparallel level of commitment and scientific temperament. Unfortunately, my initial visits to the Patent Office were not very impressive as I can easily sense poor resources and dearth of continuous training provided to Patent Examiners. Though my initial discussions with Patent Examiners disclosed their unfamiliarity with some of technical jargons used and needed to understand the invention but what was encouragingly positive that with every visit Examiners showed considerable improvement in their understanding of technical know-how and great zeal to learn. Today when I compared my initial days with recent times, I feel that Indian Patent Examiners are inching at par with US and European counterparts. It is commendable how Indian Patent Examiners have improved in past couple of years and that also with limited resources and support from the Central Government.

In past there had been constant allegations about the functioning of Indian Patent Office but in my personal opinion that is prominently due to bureaucratic policies not primarily because of Patent Examiners. Government has not only failed to keep Patent Office out its bureaucratic incompetence but also failed to provide clear guidelines about some of the complex provisions of patent law, particularly section 3(d). In fact, some of the Patent Examiners are of the opinion that the Government should clarify what qualify as “enhanced efficacy” under section 3(d) so that it can help them in uniform and consistent examination process of patent applications falling under section 3(d). Interestingly, even many of the global pharmaceutical companies are of same opinion of defining “enhanced efficacy” for clear picture of patentability but unfortunately there seems to be a strong lobby of domestic generic companies preferring to keep section 3 (d) surrounded by chaos for their own business interest. In absence of such guidelines, patent applicants and opponents all have their own way of looking into “enhanced efficacy” which eventually put Patent Examiners in dilemma that what exactly constitute “enhanced efficacy”. I personally feel very sorry about the Indian Patent Examiners who are accused of overlooking section 3 (d) which is in fact government lack of willingness to clear ‘avoidable’ confusion.

Sumatriptan Generic Space | Ranbaxy's Delay is Dr. Reddy's Gain

In an interesting piece of news reported by Khomba Singh of Economic Times, India’s largest drug manufacturer Ranbaxy has strangely missed their expected December 2008 deadline to launch generic version of Glaxo’s blockbuster anti-migraine drug Imitrex, generically known as Sumatriptan Succinate in the United States. He further reported that delay is likely due to Ranbaxy not yet received the final regulatory approval from the US Food and Drug Administration. Analysts keeping close eyes on the development projected Ranbaxy to suffer a potential loss of up to Rs. 300 crore due to regulatory delay. This seems to be a rare case where a generic manufacturer with 180 days market exclusivity delayed in launching first-time generic due to regulatory process. Last year in January, Ranbaxy settled Imitrex patent litigation with GlaxoSmithKline and announced expected launch of generic Imitrex (25mg, 50mg and 100mg strengths) in December 2008 with 180 days market exclusivity.

Ranbaxy strong business rival Dr. Reddy’s Laboratories was also in race for generic Imitrex space and was sued by GlaxoSmithKline following paragraph IV certification for Imitrex and like Ranbaxy settled patent litigation with Glaxo but in more strategic agreement and importantly before Glaxo-Ranbaxy settlement. Under the terms of agreement, Glaxo allowed Dr. Reddy’s to launch an authorized generic in the last quarter of 2008 before the expiration of the pediatric exclusivity on US5037845. In November 2008, Dr. Reddy’s as per agreement launched the authorized generic of Imitrex tablets 25mg, 50mg and 100mg in the US. Now considering Ranbaxy’s delay in launching generic Imitrex there is no doubt that it is a welcome new year for Dr. Reddy’s (and Glaxo too).

Merry Christmas!

To everyone who has read this blog, and to those who have participated in constructive discussions and debates, thank you for your continuous support. Patent Circle wishes you all a merry Christmas and best of holidays.

---

Dr. Uday, Varun & Seema

Dr. Reddy's Settle Clarinex Patent Lawsuits

After Lupin, Dr. Reddy’s Laboratories has reported to settle all pending patent infringement lawsuits with Schering and Sepracor relating anti-allergic drug Clarinex (desloratadine). Under the settlement agreement, Dr. Reddy’s will be able to sell generic versions Clarinex-D12 and Clarinex-D24 with six-months marketing exclusivity, and Clarinex Reditabs with six-months marketing co-exclusivity starting from 2012. Earlier, Schering and Sepracor have similar settlement agreements with generic manufacturers including Ranbaxy, Perrigo Co. and Watson Pharmaceuticals Inc.

Ranbaxy to Continue with Generic Business Strategy

Leading Indian newspaper Times of India (TOI) run an interesting piece of news about Ranbaxy business strategy to retain generic focus after being acquired by the Japanese Daiichi Sankyo. As rightly pointed by TOI most in industry believed that Ranbaxy will likely dilute its aggressive generic strategy, particularly paragraph IV challenges after being part of pharmaceutical drug innovator Daiichi but in an interview given to TOI, Daiichi Sankyo president and CEO Takashi Shoda told that “the company will follow a unique business model, focusing not only on innovation but also on generics”. He further added that “in developed markets like US and Japan, Ranbaxy will expand its generic business”. Further elaborating on the strategy, Ranbaxy MD Malvinder Singh said, “Our business model will continue in the US, and so will out strategy in generics. We will continue to file and evaluate First-to-file patent opportunities. We will together create a new model, where we will maintain and leverage each other strengths to benefit both (companies)”.

Considering that Daiichi has or had been in business collaborations with many innovators including Roche, Novartis, Eli Lilly and Forest Laboratories, it would be really interesting to watch how Daiichi take Ranbaxy’s business model forward in the US, in particular paragraph IV opportunities.

CitePatents.Com

Popular patent search portal FreePatentsOnline.com (FPO) has launched an informational site, www.citepatents.com, particularly to help bloggers, journalists and others to easily reference to patent information, and to provide a free patent search box for adding to websites with a single mouse click. Anyone interested in placing FPO SearchBox on their website or blog may visit CitePatents.com for the html code. Just few months FPO also launched free patent search service SumoBrain with a powerful new feature of bulk PDF downloading from a database of tens of millions of records including US patents and published applications, European patents and published applications, and WO publications. This feature obviously came handy to us, particularly in patent searches. SumoBrain also features basic and advanced search capabilities including field search, word stemming, proximity search and search term weighting. We would sincerely recommend our readers to include SumoBrain in their search tool basket.

Patent Circle Not to Report on Granted Patents

After Mint’s misleading reporting, Patent Circle has decided not to report anymore about granted pharmaceutical patents in India. Some of our readers has humbly suggested that it would be in better interest that Patent Circle must stop tracking and reporting on granted pharmaceutical patents in India and should focus writing more on general topics and various aspect of India patent laws. We sincerely appreciate our readers’ suggestion and will definitely stay away from reporting on Indian patents.

Lupin Settles Clarinex Patent Lawsuit

Lupin Ltd. has reported to settle all patent infringement lawsuits with Schering-Plough Corp. and Sepracor, Inc. relating anti-allergic drug Clarinex tablets, generically known as desloratadine. Under the terms of the settlement, Lupin will be licensed Clarinex OB listed patents and will be able to commercialize its generic Clarinex tablets on July 01, 2012 or earlier in certain circumstances. Earlier in November 2007, Sepracor and University of Massachusetts filed an infringement lawsuit against Lupin for alleged infringement of the US Patent Nos. 7,214,683 (the ‘683 patent) and 7,214,684 (the ‘684 patent).

Mint Baseless Reporting Continues

In last few days I received fair number of phone calls and emails from my readers and friends including couple of concerned Indian patent examiners commenting about Mint latest news that India has granted at least 10 patents in the past 12 months for what would appear to be mere modifications or new forms of known drugs and further cementing with inconsistency and lack of transparency in the functioning of Indian patent offices. Even some readers strongly pointed out that list of selective patents used by Mint is obtained from Patent Circle (see here and here) and more sadly accused Patent Circle for putting posts on granted patents in past and giving newspaper media ground for baseless reporting. I do accept that there had been instances where our posts are been negatively used by newspaper media but as an author I would like to clarify that our intention for carrying such posts was to send a constructive and positive message to our readers, particularly overseas readers which include foreign patent attorneys and pharmaceutical in-house counsels about Indian patent system and to remove misapprehension that Indian patent law do not merit incremental innovation. There are many newspaper journalists who not only used our post constructively but also doing a great job in building patent awareness.

In past Patent Circle exclusively brought in notice couple of patents issued to Cipla for new forms of known drugs, namely, esomeprazole and alendronate and accused Cipla of practicing double standards on patenting so-called trivial improvements. Our basis of raising fingers on such patents was our years of understanding and expertise in technical domain and Indian patent practice. Now coming back to Mint news, the reporter has accused the Indian Patent Office of oversighting Section 3 (d) of the Patents Act, 1970 and issuing patents for mere modifications or new forms of known drugs. The reporter’s allegation is based on selective 10 patents which include Cipla’s esomeprazole inclusion complex (IN219034) and alendronate monohydrate (IN219022) patents. The other patents are –

1. IN204325 titled “An eletriptan hydrobromide monohydrate and a process for the preparation of the same”

2. IN204343 titled “Polymorph of (2R, 3S, 4R, 5R, 8R,10R, 11R, 12S, 13S,14R)- 13- [[2,6-dideoxy-3-cmethyl-3-0-methyl-4-(-[(propylamino)methyl]-a-l- ribohexopryanosyl] -2-ethyl-3,4,10- trihydroxy-3,5,8,10,12,14 -hexamethyl -11- [[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylohexopyranosyl] oxa]-1-oxa-6-azacycopentadecan-15-one diphosphate”

3. IN204126 titled “4-(Diarylmethyl)-1-piperazinyl derivatives”

4. IN204151 titled “Substituted oxazoles and thiazoles derivatives as HPPAR ALPHA Activators”

5. IN204158 titled “Imidazo Pyridine Derivatives which inhibit Gastric Acid Secretion”

6. IN202128 titled “Stable crystalline polymorph Form I of (-)-4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-tri azol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro -2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one”

7. IN201649 titled “Novel succinate salt of O-desmethyl-venlafaxine”

8. IN201140 titled “Novel crystalline forms of a macrolide antibiotic CP-472,295”

Apart from four patents - IN219034 (esomeprazole inclusion complex), IN219022 (alendronate monosodium salt), IN204325 (eletriptan hydrobromide monohydrate) and IN201649 (Desvenlafaxine succinate salt) – which fortunately have drug substance generic name included in the title, the reporter seems to be not sure about what drug substances are covered by remaining six patents. In fact, the reporter seems to be not even sure whether such patents are related to human drugs or they relate to agro-chemicals/veterinary drugs. To identify such information one need to be more than an average organic chemist or patent specialist in chemistry (what the reporter referred to be so-called patent agent). For instance, IN201140 and IN204343 both issued to Pfizer are covering crystalline forms of anti-bacterial veterinary drug Tulathromycin marketed as Draxxin for the treatment of bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs. Obviously the reporter seems to be not aware of this fact because these two patent was not mentioned anywhere in public domain except one of them reported by Sandeep’s blog. I personally believe that efficacy requirement in Section 3(d) of the Patents Act, 1970 is restricted to efficacy intended for human subject not for pig, dog, cow and other animals. I hope the reporter is not weighing interests of human and pigs in same basket.

IN202128 covers polymorphic form of antifungal drug posaconazole. Remaining three patents – IN204126 issued to Sun Pharmaceutical industries Ltd. covers 4-(diarylmethyl)-1-piperazinyl derivatives having base structure similar to cetirizine, IN204151 issued to Glaxo covers substituted oxazoles and thiazoles derivatives, and IN204158 issued to AstraZeneca covers imidazo pyridine derivatives having base structure similar to structure disclosed in the US4920129 – are related to novel compounds. Obviously it is well known to a person skilled in the art that most of the new compound or group of compounds synthesized in a laboratory are chemically derived from some known chemical structure (basic chemistry concept) and by mere reading term ‘derivative’ in title or abstract of a patent no one (not even veteran chemist) would have concluded that these patents are mere derivative or modification of known substances. I am completely perplexed how a newspaper journalist came to such a conclusion, which even for me is a challenging task, and requires high-end research (not to forget complex structure search).

Indian Patent Office Launches National IPR Campaign in association with FICCI

It is well realized now that with increased relevance of Intellectual Property (IP) in this era of globalization, it is inevitable to recognize the role which IP systems play in the growth of Indian Industries. However, there is still a need to create larger public awareness about the pivotal role of IPR in globalized knowledge economy.

To meet this objective, Secretary, Department of Industrial Policy and Promotion (DIPP) announced National IPR Campaign” on World IP Day, the April 26^th, 2008. To transform this vision into reality, Office of the Controller General of Patents, Designs and Trademarks (CGPDTM) and Department of Industrial Policy and Promotion (DIPP) under Ministry of Commerce and Industry in association with Federation of Indian Chambers of Commerce and Industry (FICCI), other institutions and industry associations are jointly conducting seminars, workshops and specialized training programmes in industrially important cities across India.

The seminars in association with FICCI will be held in eight cities all over India namely Jaipur, Kanpur, Ludhiana, Delhi, Ranchi, Surat, Bhopal and Agra during December, January, February and March. The programs are highly specialized and specially oriented for the IP users, industries, innovators, and entrepreneurs and alike

At the end of the conference a quiz contest shall be held to map the success rate of the programme. The winners shall be awarded cash prize on the spot.

At the end of each seminar, the Certificate shall be issued directly by Controller General, Indian Patent Office to all the participants.

For respective dates, places, and further information Click here.

Q Corner | Minimum Period for Patent Grant

What is the minimum period in which patent can be granted in India? --- Dr. Ashwin K. Gupta, Delhi

As such there is no exact rule for calculating minimum period in which patent can be granted in India as the Indian Patent Office (IPO) has its own right to reserve timeframe for processing procedural formalities under the Patent Rules, 2003. However, if we consider that IPO effectively process its procedural formalities and the applicant promptly reply objections made by the examiner and comply with other procedural formalities within shortest possible time then a patent may be issued within 9-10 months from the date of filing of application. Obviously while calculating I am generously considering that there is no pre-grant opposition made by any concern party against grant of the patent. My basis of calculation primarily rely on the following Rules –

Rule 24 and 24A – Considering that the Applicant has made request for early publication which the Controller will publish ordinarily in one month from the date of request for publication.

Rule 24B – Considering that the applicant has requested for examination at the earliest, possibly along with the request for early publication.

Rule 24B (3) – This is the standard time period (six months) in which a First Examination Report (FER) will be dispatched to the applicant or his authorized agent from the date of the request for examination or from the date of publication whichever is later.

Rule 24B (4) – Applicant has maximum twelve months to reply the objections made by the examiner. We are considering that the applicant provide reply within shortest possible time and accepted by IPO for patent grant.

Rule 55 (1A) – Importantly, a patent cannot be granted before the expiry of a period of six months from the date of publication of the application.

The above Rules ordinarily place an application for patent a minimum of 9-10 months to grant.

Q Corner | Paragraph IV

What is Para IV and how to file Para IV? --- Dr. Jitendra Koundinya, Mumbai

This is the first question asked by our reader in our new section Q Corner. Para IV (or paragraph IV) is a statutory concept related to the US drug regulatory and patent system brought by the Drug Price Competition and Patent Term Restoration Act, 1984 also referred as “Hatch-Waxman Act.” Hatch-Waxman Act amended the Food, Drug and Cosmetic Act remarkably balancing the business interests of pioneers and generic drug manufactures, and is primarily credited for the development of the US generic drug industry. Title I of the Hatch-Waxman Act contains the drug price competition part, specifically authorizing generic drug manufactures to file Abbreviated New Drug Applications (ANDAs) along with bioavailability studies. The Act also required one of four certifications to be made when someone files an ANDA: 1) that the drug has not been patented; 2) that the patent has already expired; 3) the date on which the patent will expire, and the generic drug will not go on the market until that date passes; and 4) that the patent is not infringed or is invalid. Those certifications are now referred to as the paragraphs I, II, III and IV certifications. Title II of the Hatch-Waxman Act contains the patent term restoration part, specifically authorizing pioneers to receive an extension in patent term lost during the FDA approval process.

As a part of Para IV process, a generic applicant must do two things: 1) certify in its ANDA that the patent in question is invalid or is not infringed by the generic product and 2) notify the patent holder of the submission of the ANDA. Once the patent holder receives the ANDA notification, they have statutory discretion to file a patent infringement suit against the applicant within 45 days. If an infringement suit is filed within the 45-day period, FDA approval to market generic version is automatically stayed for 30 months. Notably, a Para IV certification can be triggered by a generic applicant for a drug product that has unexpired Orange Book (OB) listed patents and the generic applicant is seeking to market its generic equivalent before the expiration of OB patent(s).

Roche Challenged the Madras High Court's Decision

The Mumbai High Court has decided to consider Valycte patent infringement case only after eight weeks based on the order of the Madras High Court. Earlier, the Madras High Court ordered the Indian Patent Office to reexamine the patent granted to Valycte active ingredient, Valganciclovir before January 31, 2009. Roche later decided to challenge the Madras High Court’s decision and has filed a special leave petition before the Supreme Court of India. In another development, the Mumbai High Court restrained Cipla from using the trademark “Valcept” for its generic version of Valycte.

Lilly Patent Particulate Form of Tadalafil

Indian Patent Office (Chennai) has lately issued an Indian patent # 224314 (the ‘314 patent) to Lilly Icos LLC for Tadalafil particulate form and method of preparation thereof. The ‘314 patent is issued against the national phase application (PCT) # IN/PCT/2002/143/CHE claiming priority from US provisional application # 60/147,048 dated August 03, 1999 which later issued as US 6,821,975 and currently listed with the US FDA Orange Book. Marketed as Cialis by Eli Lilly, Tadalafil is one of the drug that was granted exclusive marketing right (EMR) in India against the application # 85/DEL/1995 (the 1995 application) which later got stayed by the Calcutta High Court after a petition made by Mumbai-based Ajanta Pharma.

The 1995 application covered claims for Tadalafil per se and process of preparation thereof. Considering [pre-grant opposition] filed by Ajanta Pharma, the Indian Patent Office (Delhi) last year on March 22 rejected product claims for Tadalafil per se but allowed process claims. The product claims were found obvious over the US 3,917,599 (the ‘599 patent) issued to Central Drug Research Institute (CDRI). The ‘599 patent exemplified 2-substituted-1, 2, 3, 4, 6, 7, 12, 12a-octahydropyrazino [2’, 1’:6, 1] pyrido [3, 4-b] indoles which is the base structure of Tadalafil but never suggested to be useful for treatment of erectile dysfunction.

Q Corner

Patent Circle is pleased to announce that we are starting an interesting section Q Corner where our readers can send their questions or queries related to patents and Indian patent laws, and we will try answering them within the shortest possible time. Though we will sincerely try our best responding all questions but may still drop some mostly repetitive or similar to what already been answered by us. Readers can send their questions/queries at varun@ipfeathers.com.

Disclaimer: Answer(s) provided in Q Corner nowhere constitute a legal advice and may still need to be double checked for their accuracy and current applicability.

Madras High Court Judgment | Indian Network for People v. Union of India

Recent decision by the Madras High Court ordering the Chennai Patent Office to re-examine Valcyte patent can be found here.